2/2
04:15 pm
moln
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript [Seeking Alpha]
Low
Report
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript [Seeking Alpha]
2/2
03:38 pm
moln
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready [Yahoo! Finance]
Medium
Report
Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase I/II Ready [Yahoo! Finance]
2/2
02:17 am
moln
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 [Yahoo! Finance]
Medium
Report
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026 [Yahoo! Finance]
2/2
01:00 am
moln
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
Medium
Report
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
1/28
07:29 am
moln
Molecular Partners (NASDAQ:MOLN) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
Low
Report
Molecular Partners (NASDAQ:MOLN) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.
1/27
07:19 am
moln
Molecular Partners (NASDAQ:MOLN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Medium
Report
Molecular Partners (NASDAQ:MOLN) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
1/11
03:18 pm
moln
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/11
03:00 pm
moln
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
12/18
01:00 am
moln
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference
12/11
07:31 am
moln
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics [Yahoo! Finance]
Low
Report
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics [Yahoo! Finance]
12/11
07:00 am
moln
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
Low
Report
Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics
12/8
11:41 am
moln
Molecular Partners (NASDAQ:MOLN) had its price target lowered by analysts at JPMorgan Chase & Co. from $4.00 to $3.75. They now have a "neutral" rating on the stock.
Neutral
Report
Molecular Partners (NASDAQ:MOLN) had its price target lowered by analysts at JPMorgan Chase & Co. from $4.00 to $3.75. They now have a "neutral" rating on the stock.
12/7
07:00 am
moln
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Low
Report
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
11/18
01:18 pm
moln
Molecular Partners (NASDAQ:MOLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Molecular Partners (NASDAQ:MOLN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/12
01:30 am
moln
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action [Yahoo! Finance]
Medium
Report
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action [Yahoo! Finance]
11/12
01:00 am
moln
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
Medium
Report
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action